EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Jean-Frédéric Colombel  ¹     Ana Paula Lacerda  ²     Laurent Peyrin-Biroulet  ³     Geert R. D'Haens  ⁴     Remo Panaccione  ⁵     Walter Reinisch  ⁶     Edouard Louis  ⁷     Minhu Chen  ⁸     Hiroshi Nakase  ⁹     Susan Greenbloom  ¹⁰     Aaron Duvall  ¹¹     Yuri Sanchez Gonzalez  ¹¹     Mohamed-Eslam F. Mohamed  ¹¹     Susan Rhee  ¹¹     Tian Feng  ¹¹     Elena Dubcenco  ¹¹     Julian Panés  ^12    
1 Icahn School of Medicine at Mount Sinai, New York City, United States
² AbbVie, North Chicago, United States
³ University Hospital of Nancy, Lorraine University, Vandoeuvre, France
⁴ Amsterdam University Medical Centers, Amsterdam, Netherlands
⁵ University of Calgary, Alberta, Canada
⁶ Medical University of Vienna, Vienna, Austria
⁷ University Hospital CHU of Liège, Liege, Belgium
⁸ The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
⁹ Sapporo Medical University School of Medicine, Sapporo, Japan
¹⁰ Toronto Digestive Disease Associates, Woodbridge, Canada
¹¹ Tyler Research Institute, Tyler, United States
¹² Hospital Clinic Barcelona, Barcelona, Spain

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in Crohn's disease

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)